IP Library › Granted Patent US 7,776,816
Granted Patent B2
US 7,776,816 · App. 11/336,237 · Granted Aug 17, 2010

Preserving hypoxic tissue

Assignee: Board of Regents, The University of Texas System
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,776,816
App. No.
11/336,237
Granted
Aug 17, 2010
Kind
B2
Abstract

Hypoxic tissue is preserved by prophylactically administering Stromal Derived Factor 1 Alpha (SDF-1α) before hypoxia induces cell death in the tissue.

Claims (21)

1. A prophylactic, cell-free method of preserving hypoxic myocardium tissue in a patient and following ischemia, comprising the step of administering to the tissue an effective amount of stromal cell-derived factor-1 alpha (SDF-1α) before hypoxia induces cell death in the tissue.

2. The method of claim 1 wherein the tissue is in a patient and the hypoxia is ischemic.

3. The method of claim 1 wherein the tissue is in a patient, the hypoxia results from an ischemic myocardial infarction, and the tissue is myocardium immediately surrounding the infarct zone.

4. The method of claim 1 wherein the SDF-1α is administered intravenously.

5. The method of claim 1 wherein the SDF-1α is administered by injection into the tissue.

6. The method of claim 1 wherein the SDF-1α is administered within 24 hours of onset of the hypoxia.

7. The method of claim 1 wherein the SDF-1α is administered within 12 hours of onset of the hypoxia.

8. The method of claim 1 wherein the SDF-1α is administered within 6 hours of onset of the hypoxia.

9. The method of claim 1 wherein the SDF-1α is administered within 3 hours of onset of the hypoxia.

10. The method of claim 1 wherein the SDF-1α is administered within 1 hour of onset of the hypoxia.

11. The method of claim 1 further comprising the subsequent step of detecting a resultant preservation of the tissue.

12. The method of claim 1 further comprising the subsequent step of detecting a resultant preservation of the tissue within 48 hours of onset of the hypoxia.

13. The method of claim 1 further comprising prior to the administering step the step of detecting the hypoxia.

14. The method of claim 1 wherein administered is a composition consisting essentially of the amount of SDF-1α.

15. The method of claim 1 wherein the SDF-1α is administered directly to the tissue in the range of 30 to 3,000 ng.

16. The method of claim 1 wherein the SDF-1α is administered directly to the tissue in the range of 100 to 1000 ng.

17. The method of claim 1 wherein the amount of SDF-1α is administered systemically in the range of 15 to 1,500 ug.

18. The method of claim 1 wherein the amount of SDF-1α is administered systemically in the range of 50 to 500 ug.

19. The method of claim 1 , wherein treatment with SDF-1α ceases within 48 hours of the onset of the hypoxia.

20. The method of claim 1 , wherein treatment with SDF-1α ceases within 24 hours of the onset of the hypoxia.

21. The method of claim 1 , wherein treatment with SDF-1α ceases within 12 hours of the onset of the hypoxia.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 20, 2006
From: SRIVASTAVA, DEEPAK; SAXENA, ANKUR
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 017505/0446 →
Continuity (1)
Related Publication 20070172811A1 · Jul 26, 2007